Daratumumab + Gene Therapy is under clinical development by Indapta Therapeutics and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Daratumumab + Gene Therapy’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Daratumumab + Gene Therapy overview
Gene therapy in combination with daratumumab is under development for the treatment of relapsed and refractory multiple myeloma, multiple sclerosis and non-Hodgkin lymphoma. The drug candidate comprises of daratumumab combined with FcRy adapter lacking (G-NK) cells. Daratumumab acts by targeting cells expressing CD38 (ADP ribosyl cyclase/cyclic ADP ribose hydrolase 1). It is being developed based on universal natural killer (NK) cell therapy platform.
The drug was under development for the treatment of solid tumors.
Indapta Therapeutics overview
Indapta Therapeutics (Indapta) is a biotechnology company focused on developing and commercializing a proprietary, allogeneic FcR?-deficient natural killer (G-NK) cell therapy to treat multiple types of cancer. Indapta is headquartered in Houston, Texas, the US.
For a complete picture of Daratumumab + Gene Therapy’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
